The irony is the better the prospect of a drug, the less people understand the potential. If you have the 50th anti-PD1 antibody then everyone know what you have even if the commercial potential is limited. If you have a drug on the cutting edge then few will understand why it is so compelling, despite the commercial prospects being outstanding.
The good news is good clinical data changes all this.
General Comments / Chat, page-8621
-
- There are more pages in this discussion • 3,350 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.045(3.01%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.52 | $1.45 | $62.74K | 42.47K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 14110 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 666 | 1 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |